薛向东，长聘教轨副教授，课题组组长，博士生导师，上海市海外高层次引进人才。
博士毕业于中国科学院国家纳米科学中心，师从梁兴杰研究员。2015年至2020年，分别在美国华盛顿大学（Samuel Wickline课题组）和加州大学戴维斯分校（Yuanpei Li课题组）从事博士后研究工作。2020年12月全职加入欧宝app官方网站下载药学院，长期致力于：基于纳米材料的癌症精准诊疗以及“诊断-治疗”相关性的探究，以期发展出更优的癌症防治方案。目前已发表高水平SCI论文50余篇，论文被引超过3200次，H因子27。其中包括以第一或通讯作者在 Nature Nanotechnology, Nature Communications, Advanced Materials, ACS Nano, Biomaterials, Advanced Functional Materials等国际权威刊物上发表的论文20余篇（IF>220），并被F-1000，福布斯，科学日报，美国化学学会等知名媒体报道。主持国自然青年和面上基金各1项，获授权PCT 国际专利 2项（1项已转让），中国专利 5 项（1项已转让）。同时，薛向东为《Exploration》期刊青年编委，《International Journal of Molecular Sciences》(IF=6.2)和《Journal of Functional Biomaterials》（IF=4.51）的客座主编，上海市药学会药剂学专委会青年委员（基础药剂学组），中国生物物理学会会员，中国抗癌协会会员，美国癌症研究协会（AACR）会员；并长期担任Biomaterials, Advanced Sciences, Small, ACS Applied Material & Interface, Chemical Engineering Journal, Acta Biomaterialia, Journal of Controlled Release, Molecular Pharmaceutics等20余国际学术期刊的审稿人。

诚聘博士后青年学者！

课题组招收博士和硕士研究生，热忱欢迎有药学、化学、材料和生物医学研究背景的青年才俊加入！

课题组面向“精准医疗”和人民“大健康”需求，基于纳米技术发展精准的影像诊断和药物治疗策略，以期发展出优于临床手段的癌症个性化治疗和精确诊断技术和方法。具体为：

o 智能小分子药物自组装递送系统的构建及其对相关疾病的治疗和成像
o 基于可调谐造影剂的MRI及相关成像技术对早期癌症的精确诊断
o 免疫调控和免疫治疗对晚期转移型癌症的治疗

23. Li, L.; Lindstrom, A.; Birkeland, A.; Tang, M.; Lin, T-Y.; Zhou, Y.*; Xiang, B.*; Xue, X.*; Li, Y.*, Deep tumor-penetrating nano-delivery strategy to improve diagnosis and therapy in patient-derived xenograft (PDX) oral cancer model and patient tissue. Nano Research 2023, 16, 2927–2937. IF=10.269

-----------------------------------------------------------

22. Zhu, Z.; Ma, A.-H.; Zhang, H.; Lin, T.-Y.; Xue, X.; Farrukh, H.; Zhu, S.; Shi, W.; Yuan, R.; Cao, Z.; Chittepu, V. C. S. R.; Prabhala, R.; Li, Y.; Lam, K. S.; Pan, C.-x.*, Phototherapy with Cancer-Specific Nanoporphyrin Potentiates Immunotherapy in Bladder Cancer. Clinical Cancer Research 2022, OF1–OF12. IF=13.312

21. Xue, X.*; Qu, H.; Li, Y.*, Stimuli-Responsive Crosslinked Nanomedicine for Cancer Treatment. Exploration 2022, 20210134. IF=N/A

20. Chen, H.; Timashev, P.; Zhang, Y.; Xue, X.*; Liang, X.-J.*, Nanotechnology-based combinatorial phototherapy for enhanced cancer treatment. RSC Advances 2022, 12 (16), 9725-9737. IF= 4.036

19. Zhang, Y.†; Qu, H.†; Xue, X.*, Blood-brain barrier penetrating liposomes with synergistic chemotherapy for glioblastoma treatment. Biomaterials Science 2022, 10 (2), 423-434. IF=7.59

18. Zhao, T.; Liang, C.; Zhao, Y.; Xue, X.; Ma, Z.; Qi, J.; Shen, H.; Yang, S.; Zhang, J.; Jia, Q.; Du, Q.; Cao, D.; Xiang, B.*; Zhang, H.*; Qi, X., Multistage pH-responsive codelivery liposomal platform for synergistic cancer therapy. Journal of Nanobiotechnology 2022, 20 (1), 177. IF=9.464

--------------------------------------------------------------------------------------------------------------------------------------------

17. Xue, X.†; Ricci, M.†; Qu, H.; Lindstrom, A.; Zhang, D.; Wu, H.; Lin, T.-Y.; Li, Y.*, Iron-crosslinked Rososome with robust stability and high drug loading for synergistic cancer therapy. Journal of Controlled Release 2021, 329, 794-804. IF=11.47

16. Wang, Z.†; Xue, X.†; Lu, H.; He, Y.; Lu, Z.; Chen, Z.; Yuan, Y.; Tang, N.; Dreyer, C. A.; Quigley, L.; Curro, N.; Lam, K. S.; Walton, J. H.; Lin, T.-y.; Louie, A. Y.; Gilbert, D. A.; Liu, K.; Ferrara, K. W.; Li, Y.*, Two-way magnetic resonance tuning and enhanced subtraction imaging for non-invasive and quantitative biological imaging. Nature Nanotechnology 2020, 15, 482–490. IF=39.213. 被中外媒体报道99次，包括F1000，福布斯 (Forbes)，科学日报 (ScienceDaily)，新浪网，生物艺术，纳米人等知名媒体。F1000 (Rated Exceptional)。

15. Xue, X.†; Huang, Y.†; Bo, R.; Jia, B.; Wu, H.; Yuan, Y.; Wang, Z.; Ma, Z.; Jing, D.; Xu, X.; Yu, W.; Lin, T.-y.; Li, Y.*, Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment. Nature Communications 2018, 9 (1), 3653. IF= 17.7. 申请PCT国际专利一项。基于该工作的纳米药物已帮助实验室拿到600余万美元的基金资助，包括1个小型企业创新研究基金 (SBIR) 和2个美国国立卫生院的研究项目基金 (R01)。

14. Xue, X.; Zhao, Y.; Dai, L.; Zhang, X.; Hao, X.; Zhang, C.; Huo, S.; Liu, J.; Liu, C.; Kumar, A.; Chen, W.-Q.; Zou, G.; Liang, X.-J.*, Spatiotemporal Drug Release Visualized through a Drug Delivery System with Tunable Aggregation-Induced Emission. Advanced Materials 2014, 26 (5), 712-717. IF= 32.08. 首次用聚集诱导发光分子递送药物的工作之一，被聚集诱导发光概念的提出者唐本忠院士撰文，以“有价值的化学”高亮报道在美国化学学会网站上.

13. Xue, X.; Bo, R.; Qu, H.; Jia, B.; Xiao, W.; Yuan, Y.; Vapniarsky, N.; Lindstrom, A.; Wu, H.; Zhang, D.; Li, L.; Ricci, M.; Ma, Z.; Zhu, Z.; Lin, T.-y.; Louie, A. Y.; Li, Y.*, A nephrotoxicity-free, iron-based contrast agent for magnetic resonance imaging of tumors. Biomaterials 2020, 257, 120234. IF=15.03.

12. Xue, X.†; Huang, Y.†; Wang, X.; Wang, Z.; Carney, R. P.; Li, X.; Yuan, Y.; He, Y.; Lin, T.-y.; Li, Y.*, Self-indicating, fully active pharmaceutical ingredients nanoparticles (FAPIN) for multimodal imaging guided trimodality cancer therapy. Biomaterials 2018, 161, 203-215. IF=15.03.

11. Xue, X.†; Jin, S.†; Zhang, C.; Yang, K.; Huo, S.; Chen, F.; Zou, G.; Liang, X.-J.*, Probe-Inspired Nano-Prodrug with Dual-Color Fluorogenic Property Reveals Spatiotemporal Drug Release in Living Cells. ACS Nano 2015, 9(3), 2729-2739. IF= 18.02.

10. Wang, Z.†; Xue, X.†; He, Y.; Lu, Z.; Jia, B.; Wu, H.; Yuan, Y.; Huang, Y.; Wang, H.; Lu, H.; Lam, K. S.; Lin, T.-Y.; Li, Y., Novel Redox-Responsive Polymeric Magnetosomes with Tunable Magnetic Resonance Property for In Vivo Drug Release Visualization and Dual-Modal Cancer Therapy. Advanced Functional Materials 2018, 0 (0), 1802159. IF=19.92.

9. Xue, X.†; Jin, S.†; Li, Z.; Zhang, C.; Guo, W.; Hu, L.; Wang, P. C.; Zhang, J.; Liang, X.-J.*, Through-Bond Energy Transfer Cassette with Dual-Stokes Shifts for “Double Checked” Cell Imaging. Advanced Science 2017, 1700229. IF=17.52.

8. Yuan, Y.; Bo, R.; Jing, D.; Ma, Z.; Wang, Z.; Lin, T.-y.; Dong, L.; Xue, X.*; Li, Y.*, Excipient-free porphyrin/SN-38 based nanotheranostics for drug delivery and cell imaging. Nano Research 2020, 13, 503-510. IF=10.26.

7. Yu, W.†; Xue, X.†; Ma, A.-H.; Ruan, Y.; Zhang, H.; Cheng, F.; Li, Y.*; Pan, C.-X.*; Lin, T.-Y.*, Self-Assembled Nanoparticle-Mediated Chemophototherapy Reverses the Drug Resistance of Bladder Cancers through Dual AKT/ERK Inhibition. Advanced Therapeutics 2020, 3, 2000032. IF=5.002.

6. Xue, X.; Lindstrom, A.; Qu, H.; Li, Y.*, Recent advances on small-molecule nanomedicines for cancer treatment. WIREs Nanomedicine and Nanobiotechnology 2019, 12 (3), e1607. IF=10.86.

5. Xue, X.; Lindstrom, A.; Li, Y.*, Porphyrin-Based Nanomedicines for Cancer Treatment. Bioconjugate Chemistry 2019, 30 (6), 1585-1603. IF=6.06.
4. Yuan, Y.; He, Y.; Bo, R.; Ma, Z.; Wang, Z.; Dong, L.; Lin, T.-y.; Xue, X.*; Li, Y.*, A facile approach to fabricate self-assembled magnetic nanotheranostics for drug delivery and imaging. Nanoscale 2018, 10 (46), 21634-21639. IF=8.3.

3. Yang, X.†; Xue, X.†; Luo, Y.; Lin, T.-y.; Zhang, H.; Lac, D.; Xiao, K.; He, Y.; Jia, B.; Lam, K. S.*; Li, Y.*, Sub-100nm, long tumor retention SN-38-loaded photonic micelles for tri-modal cancer therapy. Journal of Controlled Release 2017, 261, 297 - 306. IF=11.47.

2. Xue, X.; Xu, J.; Wang, P. C.; Liang, X.-J.*, Subcellular behaviour evaluation of nanopharmaceuticals with aggregation-induced emission molecules. Journal of Materials Chemistry C 2016, 4, 2719-2730. IF=8.06.

1. Xue, X. †; Zhao, Y. †; Zhang, X.; Zhang, C.; Kumar, A.; Zhang, X.; Zou, G.; Wang, P.; Zhang, J.; Liang, X.-J.*, Phenylboronic acid-functionalized magnetic nanoparticles for one-step saccharides enrichment and mass spectrometry analysis. Biophysics Report 2015, 1 (2), 61-70. IF=N/A.

承担基金项目：
1. 国家自然科学基金青年项目，项目名称：替莫唑胺功能化脂质体对耐药型多形性胶质母细胞瘤的治疗，主持（已结题)
2. 国家自然科学基金面上项目，项目名称：双阶导向的变形递药系统及其对多形性胶质母细胞瘤“ 内外兼施”的治疗方案，主持（在研）